Pharmasset PSI-7977 43/47 patients undetectable levels

StephenW

Pharmasset Climbs After Study Result Released
        
                        Share   
   
                                         
From Associated Press (September 6, 2011)
Drug developer Pharmasset Inc. hit a "home run" with results from a mid-stage study of a potential hepatitis C virus treatment, according to a Citi analyst.
THE SPARK: Pharmasset, based in Princeton, N.J., said Tuesday results from a study of the drug candidate labeled PSI-7977 showed that 91 percent of the subjects enrolled, or 43 out of 47 patients, had undetectable levels of the virus 12 weeks after their treatment stopped. The company is studying a 400-milligram dose of PSI-7977 used in combination with two other treatments in patients with a form of the hepatitis C virus who had not been treated previously.
Pharmasset will monitor the patients for a total of 24 weeks, or six months, after treatment stops. Results from the study will be presented in November at a meeting of the American Association for the Study of Liver Diseases.
Pharmasset说，总部设在新泽西州普林斯顿，周二从标有PSI -7977的候选药物的研究结果表明，有91％的受试者登记，或43/47例，病毒检测不到的水平，12周后，其治疗停止。该公司正在研究的7977 PSI -400毫克的剂量，在两个与C型肝炎病毒，以前尚未处理的形式的患者的其他治疗方法结合使用。
Pharmasset将监测，共24个星期，或六个月病人，经治疗后停止。从研究的结果将提交11月在美国协会肝病研究会议。
THE BIG PICTURE: Pharmasset has no products on the market. The company said in July its fiscal third-quarter loss widened to $22.6 million, or 60 cents per share, due to continued development of the drug. It reported $246,000 in revenue, which comes from partnership payments from Swiss drugmaker Roche Holding AG.
THE ANALYSIS: Analyst Dr. Yaron Werber said in a Tuesday morning research note the study's cure rate was the highest ever seen, and it surpassed his expectation of between 85 percent and more than 90 percent.
"This should cement confidence in the long-term outlook, in our view," Werber wrote.
In August, Werber said PSI-7977 will become part of the backbone for hepatitis treatments, due in part to its high potency.




(6.合.彩)足球.篮球...各类投注开户下注

第一投注现金网:招代理年薪10万以上:yyu.cc

把握当下

91%丙肝病人dna12周内转阴
Analyst Dr. Yaron Werber said in a Tuesday morning research note the study's cure rate was the highest ever seen
分析员Yaron Werber博士在周二早上的研究笔记中说该研究治愈率目前为止最高

丙肝的治疗终点是dna转阴吗？应该还有别的吧？

StephenW

把握当下 发表于 2011-9-7 19:03
91%丙肝病人dna12周内转阴
Analyst Dr. Yaron Werber said in a Tuesday morning research note the study' ...

HCV is a rna virus. 91%丙肝病人virus 12周内转阴. 我不知道很多关于HCV。

把握当下

StephenW 发表于 2011-9-7 19:24
HCV is a rna virus. 91%丙肝病人virus 12周内转阴. 我不知道很多关于HCV。

哦，我搞错了，是病毒转阴

听说丙肝比较好治。。。

StephenW

回复 把握当下 的帖子

是的，需要用干扰素，治愈率>> 50％.